The present application relates to a kind of compound 2-[(full-E)3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracosaalkyl]-5,6-dimethoxy-3-methyl-p-
benzoquinone crystal form and its preparation method and application, belong to
chemical engineering crystallization field.The technical problem to be solved is to provide a
crystal form with significantly improved stability, significantly improve the light stability of the compound, and further more conducive to storage and transportation, better ensure the consistency of
therapeutic effect, reduce the effect fluctuation or adverse reaction caused by
dissolution difference.Characteristic
diffraction peak of X-
ray powder diffraction pattern expressed by 2θ value ± 0.2° using Cu-Kα
radiation includes 4.70, 6.25, 15.65, 17.22, 19.18, 20.45, 27.39.